The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets
Dawn Q. Chong(National Cancer Centre Singapore), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai)
Cited by 105
Related Papers
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma
|Liver International|2019|591